Dupilumab, a drug tested at UR Medicine, recently earned approval from the Food and Drug Administration.
The medicine will bring relief to adults with eczema or atopic dermatitis. The condition is characterized by dry skin, red lesions that may crust or ooze, skin thickening and itching, sometimes covering as much as 95 percent of the patient’s body. This can lead to skin wounds, infections, sleep disturbance and depression.
UR Medicine dermatologist Linda Beck, leading researcher in the drug’s clinical trials, said Dupilumab is a game-changer for patients. It is the first medication proven effective for adults with the often-debilitating disease.